INTRODUCTION
Vincristine (VCR), a Vinca (periwinkle) alkaloid, is an effective chemotherapeutic agent. It is widely used in combination with other agents in clinical cancer treatment, including lung cancer. However, resistant cells occasionally arise, causing a great hindrance in the fight against cancer. Extensive studies in dealing with drug resistance have been accumulated with in vitro cell model systems, but they are not necessarily reproduced in vivo. VCR-resistant tumour-cell lines have previously been established. Among these, cell lines selected by microtubule blockers, such as VCR and colchicine, are often associated with multidrug resistance (MDR), a phenomenon resulting from overexpression of a membrane-anchored P-glycoprotein, which functions like an efflux pump for the drug [1, 2] . Nevertheless, the extent of MDR in these cells is not always consistent with the level of Pglycoprotein, suggesting that additional mechanisms may also participate in the MDR phenotype. For example, an increased level of GSH was detected in an MDR small-cell lung-cancer cell line that does not overexpress P-glycoprotein [3] . Non-Pglycoprotein-mediated MDR has also been documented, some of which is believed to precede P-glycoprotein expression during the development of MDR [4] [5] [6] [7] [8] [9] [10] [11] [12] . It has been shown that human cells with slight resistance (less than 10-fold) to colchicine or VCR do not overexpress the P-glycoprotein genes; however, cells which are treated by stepwise exposure to the selecting agents and which acquire greater resistance are associated with overexpression of P-glycoprotein (see, e.g. [13] ). Thus obtaining more information about non-P-glycoprotein pathway(s) is important for the understanding of the development of MDR.
In the present study we established a VCR-resistant subline from human lung-cancer PC-9 cells which displays a reduced cells, suggesting that VCR resistance in PC-9/VCR cells results essentially from reduced drug accumulation. It is worth noting that, whereas reduced drug accumulation in the PC-9/VCR cells was susceptible to modulation by ascorbic acid, the increased efflux rate characteristic of the resistant cells was not. Further, there was a higher efflux rate in resistant cells than in parental cells. DNA Southern-and RNA Northern-blot hybridization analyses indicate that PC-9/VCR cells do not contain amplified mdr genes or overexpress P-glycoprotein. In addition, the calcium-channel blocker verapamil, which acts as a competitive inhibitor of drug binding and efflux, did not affect the resistant phenotype of PC-9/VCR cells. These findings suggest an ascorbic acid-sensitive drug uptake mechanism which is important in mediating VCR resistance per se in human lung-cancer cells; this differs from the P-glycoprotein-mediated MDR mechanism. drug accumulation and does not overexpress P-glycoprotein. More interestingly, we found that L-ascorbic acid could inhibit cellular resistance to VCR, the inhibition being associated with restoration of drug accumulation. L-Ascorbic acid is effective in modulating the growth of human leukaemia cells [14] [15] [16] , and potentiating the inhibitory effect of certain agents on growth of cultured neuroblastoma cells [17] . A potential value of ascorbic acid in cancer treatment comes from differential responses of cancer cells and their normal counterpart to the agent (see, e.g., [18] ). It has been shown at the molecular level that ascorbic acid causes DNA strand breaks and cross-links in human neuroblastoma cells and prevents their growth without affecting normal neuronal cells [19] . We demonstrate here that ascorbic acid could also reverse cellular resistance to VCR by modulating drug accumulation. [20] were maintained in Abbreviations used: DMEM, Delbecco's modified Eagle's medium; L-PAM, melphalan; MDR, multidrug resistance; VCR, vincristine. § To whom correspondence should be addressed.
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RPMI-1640 and DMEM respectively. The resistant cell line PC-9/VCR was established by intermittent exposure of PC-9 cells to VCR. The drug concentration was increased from 5 x 104 ,ug/ml initially to 0.02 ,ug/ml in 2-fold increments. Exposure to each concentration of the drug for 4-6 days was followed by 2-4 weeks growth in the absence of drug to allow for recovery between each treatment. The selected resistant cell line, named PC-9/VCR, was cultured continuously in medium containing 0.02 /tg/ml VCR to maintain the resistant phenotype. The acquired resistance of the cells to the drug is defined as the ratio of IC50, the drug concentration inhibiting cell survival by 500% of that of the parental cells. Cytotoxicity was assayed with the MTT dye 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (Sigma) as previously described [21] . In some cases, the colony-forming assay [22] was also used to determine clonogenicity of cells.
Drug-accumulation analysis
Drug-uptake and -efflux determinations were carried out by a modification of the method of Lemontt et al.[28] . For druguptake analysis, at specific intervals after mixing 106 cells with 0.5 ml of serum-free medium containing 5 25 'C. At specific times, 0.8 ml of the cell suspension (1 x 106 cells) were extracted as described above. The aqueous medium (0.8 ml) remaining over the oil was removed for counting of 3H radioactivity. All the drug-accumulation studies were carried out at 25 'C. For the effects of ascorbic acid on drug uptake, medium containing 25 ,g/ml ascorbic acid was preincubated with cells for 20 min before the labelled drug was added. For drug-efflux determinations, cells were preincubated with the labelled drug for 3 h before ascorbic acid was added. Cells were then incubated for 1, 2 or 3 h before harvesting for radioactivity counting.
Cancer Institute, Amsterdam, The Netherlands) as previously described. Probes were purified by electrophoresis on an NA45 membrane (Schleicher and Schuell) and radiolabelled by the random-priming method with [a-32P]dCTP to a specific radioactivity of 108 c.p.m./,ug of DNA as described in [26] . The labelled probe was purified by passage through a resin (Sepharose G-50; Pharmacia)-loaded spin column.
RESULTS
Characteristics of the sensitive and resistant cells A VCR-resistant human lung-cancer cell line (PC-9/VCR) was established. Cytotoxicity, determined by the MTT-dye method (Figure 1 a) or colony-forming assay (Figure lb) , exhibited a 12-fold and 10-fold increase in resistance respectively to the selecting drug. The patterns of the survival curves by both methods are similar, showing a 'shoulder' response at low concentrations of VCR (within 10-2 jug/ml) in the resistant cells. In contrast, the parental cells lacked a similar tolerance response. At drug concentrations higher than 10-2 ,ug/ml, both cell lines displayed similar exponential responses. The IC50 was 0.008 and 0.1 utg/ml for parental and resistant cells respectively (also see below). There is a 12.5-fold increase in resistance in PC-9/VCR cells. As estimated by clonogenic ability, VCR cells acquired 10-fold resistance, results comparable with the MTT-dye data. The acquired resistance phenotype was stable, as evidenced by the persistence of drug resistance after removal of VCR from the testing medium for at least 1 month (results not shown). Some other characteristics of the established PC-9/VCR cells are shown in Table 1 . Approx. 40 % of the resistant cells attached to the culture vessel, and the other 600 grew stably as the parental cells in suspension. The significance of adherent growth of the resistant cells has yet to be studied.
Cross-resistance of PC-9/VCR cells to anticancer agents
Resistance of PC-9/VCR cells to other anticancer agents was determined by the MTT-dye assay. Calculated IC50 values are listed in Table 2 . PC-9/VCR cells also showed high resistance to DNA and RNA blot hybridizations, and probes 
Inhibition of drug resistance by ascorbic acid In resistant cells
The effect of ascorbic acid on cellular response to VCR was measured by the MTT-dye assay. To eliminate complications from the modulating agent itself, a non-toxic or low cytotoxic concentration of ascorbic acid was used. Figure 2 (a) shows cellular response to ascorbic acid. Concentrations below 10 ,ug/ml had no profound toxic effect on either parental (El) or resistant (-) cells. At 25 ,ug/ml, ascorbic acid slightly inhibited cell growth in both to a similar extent. The modulating effect of ascorbic acid on the VCR response of cells was studied with this background. For parental cells (Figure 2b ), no significant sensitization by 25 ,ug/ml ascorbic acid (A) was detected. Neither of the lower concentrations (1 and 10 ,ug/ml) of ascorbic acid addressed the modulating effect on the VCR cytotoxicity (results not shown). In contrast, 25 ,g/ml ascorbic acid significantly lowered the resistant-cell proliferation (Figure 2c, *) . Lower concentrations of ascorbic acid were also effective in sensitizing VCR toxicity. These results indicate that a non-toxic (10 ,ug/ml) or toxic (25 ,ug/ml) concentration of ascorbic acid is effective in sensitizing the killing effect of VCR in resistant cells, but not in parental cells.
To investigate whether the same cytotoxic modification exists in the MDR cells, effects of ascorbic acid on VCR toxicity were compared in SW620 and resistant SW620/MDR cells ( Table 3) . IC50 of adriamycin toxicity with or without ascorbic acid during treatment is shown in the Table. The extent of reduction in toxicity (right column of the Table) was calculated from the IC50 values without ascorbic acid divided by the IC50 with ascorbic acid. For SW620 and SW620/MDR cells it was 1.04 and 0.97 respectively. The data indicate that ascorbic acid effectively reversed acquired resistance of PC-9/VCR cells (see Figure 2) ; by contrast, ascorbic acid caused very little, if any, effect on VCR resistance of SW620/MDR cells (Table 3) . These results are consistent with the conclusion that the mechanism of drug resistance in PC-9/VCR cells is different from the P-glycoproteinmediated resistance in SW620/MDR cells. * IC50 is the drug concentration effective in inhibiting 50% of the cell growth measured by the MTT-dye assay after 4 days of continuous exposure to the drug; results are means + S.D. for three determinations.
t Fold resistance was determined by the ratio of IC50 of PC-9/VCR to the IC50 of PC-9. (Figure 4) . In parental cells, no reduction in the amount of drug was detected within the first hour, followed by a linear pattern of drug release (20 % /h). This response was consistently observed in the presence or absence of ascorbic acid. In contrast, resistant cells effectively lost the drug from the cells after drug removal (35 %/h). Ascorbic acid did not affect the pattern of drug efflux compared with the reaction without ascorbic acid. The efflux rate in resistant cells is 1.8-fold higher than the efflux rate in parental cells. In any case, the function of drug efflux is independent of ascorbic acid in both cell lines. Therefore this modulating agent only acts on uptake, not efflux, of the drug.
Lack of overexpression of the mdrl gene in resistant cells
We have previously shown that a P-glycoprotein-mediated MDR human colon-cancer cell line has acquired the ability to decrease drug accumulation inside the cell by pumping the drug out [27] . This characteristic holds true for a variety of ,hydrophobic drugs, which is typical of an MDR phenotype. It is reasonable to speculate then that the PC9/VCR cells may overexpress P-glycoprotein because they developed an enhanced ability to pump the drug out (see Figure 4) . However, the DNA Southernand RNA Northern-blot hybridizations did not indicate a detectable increase in amplification or overexpression of the Pglycoprotein (or mdrl) gene in the PC9/VCR cells ( Figure 5 ). For DNA analysis, HindlIl-or EcoRI-digested genomic DNA showed no detectable mdr in PC-9 and PC-9/VCR. As controls, samples from the above-described MDR colon-cancer cell line and its parental line were run in parallel. sublethal concentration of verapamil (1 ,ug/ml) on VCR toxicity was compared in parental and resistant cells (Table 4 ). SW620 and SW620/MDR cells were used as controls. The IC50 of the two pairs of cell lines is indicated in the presence or absence of verapamil. Resistance to VCR is reduced by verapamil only 1.07-and 1.09-fold respectively in PC-9 and PC-9/VCR cells. By contrast, the resistance of SW620 and SW620/MDR cells to VCR is reduced by verapamil 1.03-and 32-fold respectively. The results indicate that verapamil affected VCR toxicity only in P-glycoprotein-overexpressing SW620/MDR cells, but not in PC-9/VCR cells, supporting the notion that the drug resistance in PC-9/VCR cells is probably not due to P-glycoprotein.
inhibiting the formation of mitotic spindles, thereby preventing cells from dividing [29, 31, 32] . In addition, VCR may modulate the shape of cells through interaction with the cytoskeleton and may affect functions of the cell membrane [16] . Therefore, control by the cell membrane of VCR accumulation may play a role in determining the drug's effect on cells. It is conceivable that loss of cell response to VCR may result from an altered membrane function. This is supported by studies on drug accumulation (see Figures 3 and 4) showing that PC-9/VCR cells displayed a reduced drug uptake and an increased drug efflux. It is worth noting that altered drug accumulation in PC-9/VCR cells is insensitive to verapamil, an effective inhibitor of the P-glycoprotein pump. In addition, PC-9/VCR cells do not overexpress P-glycoprotein. Taken together, these results strongly suggest that the altered membrane function ofPC-9/VCR cells is unlikely to be dependent on P-glycoprotein. Recently, Cole et al. [33] have isolated a drug transporter gene from human small-cell lung cancer cells that is distinct from P-glycoprotein. The mRNA of the gene encodes a member of the ATP-binding cassette transmembrane transporter superfamily. The overexpression of this gene in MDR HeLa cells and inherently resistant non-small-cell lung-cancer cell lines suggests that this protein may play a role in resistance in the PC-9/VCR cells. Interestingly, ascorbic acid effectively inhibited the resistance of PC-9/VCR cells to VCR. It has been shown that the oxidized form of ascorbic acid alone inhibits the growth of Ehrlich ascites tumour, L1210 leukaemia, P388 leukaemia, and prolongs animal lifespan [34, 35] . Furthermore, it has recently been reported that ascorbic acid can serve as an essential antioxidant in the presence of severe GSH deficiency, and that it protects animals against cataracts [36] . Although the exact mechanism whereby ascorbic acid sensitizes PC-9/VCR cells to VCR is not clear, it is possible that the drug-accumulation-associated membrane activity detected in this study is modulated by ascorbic acid through an oxidation mechanism. Drug accumulation analyses indicate that the reduced drug uptake in PC-9/VCR cells is restored by ascorbic acid and is associated with the loss of VCR resistance. The results suggest that the altered membrane drug-transport activity in resistant cells is important in determining VCR resistance. Since ascorbic acid also has an inhibitory effect on the resistance and the uptake of colchicine in PC-9/VCR cells (E.-J. Song, C. D. Chiang, V. C. Yang and C. C.-K. Chao, unpublished work), the altered membrane activity is likely also to be responsible for 'gating' colchicine from the cells. Thus the resistant PC-9/VCR subline is especially useful in studying responses of cells to microtubule inhibitors. Perhaps alteration of this ascorbic acid-sensitive membrane activity is an early step towards the establishment of MDR phenotype. However, the membrane activity is unlikely to be due to P-glycoprotein, since the drug-sensitivity of the MDR colon-cancer cells (described in [32] ) is not affected by ascorbic acid. This novel mechanism of drug resistance may be an additional resistance pathway encountered in clinical cancer therapy.
DISCUSSION
In the present study we 
